Rimonabant can lower heart disease risk factors
NEW YORK, Thursday (Reuters)
Rimonabant, know by the trade name Acomplia, results in weight loss
and improves the risk profile in obese patients with high cholesterol
who are at increased risk of cardiovascular disease, new study findings
show.
Reuters Health has previously reported that rimonabant is effective
in reducing weight. The current study, supported by Sanofi-Aventis and
published in The New England Journal of Medicine, included overweight or
obese patients at high risk for cardiovascular disease.
Dr. Jean-Pierre Despres, from Laval University in Ste.-Foy, Quebec,
Canada, and his associates randomly assigned 340 subjects to rimonabant
5 mg, 344 to rimonabant 20 mg, and 334 to placebo. All of the patients
were instructed to maintain a low-calorie diet.
At the end of 12 months, those in the placebo group lost an average
of 2.3 kilograms (kg), compared with a weight loss of 4.2 kg in the
lower-dose rimonabant group and 8.6 kg in the higher-dose rimonabant
group.
Weight loss occurred during the first months and then stabilized
without regain throughout the rest of the study period. Reductions in
waist circumference followed a similar pattern.
Triglycerides fell by 15.8 percent among those taking the higher dose
of rimonabant, while remaining steady in the other two groups. HDL
cholesterol, the “good” cholesterol, increased by 12.2 percent in the
placebo group, 15.6 percent in the lower-dose rimonabant group and 23.4
percent in the higher-dose rimonabant group.
The prevalence of the metabolic syndrome fell to 41.0 percent, 40.0
percent and 25.8 percent, respectively, from an overall prevalence of 54
percent at the start of the study. The metabolic syndrome is a cluster
of conditions such as high blood pressure and high blood sugar levels
that raise the risk of heart disease and diabetes.
The higher dose of rimonabant also resulted in lower blood sugar
levels and lower C-reactive protein levels, high levels of which are
associated with diabetes and heart disease, respectively.
The drug also resulted in lower blood pressure and higher levels of
adiponectin. |